Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Lixte Biotechnology Holdings ( (LIXT) ) is now available.
On November 24, 2025, LIXTE Biotechnology Holdings completed the acquisition of Liora Technologies Europe Ltd., a UK-based company specializing in proton therapy systems for cancer treatment. This acquisition marks LIXTE’s entry into the radiotherapy segment, as Liora’s LiGHT System offers advanced proton therapy solutions. The transaction includes a royalty agreement where LIXTE will pay Orbit Capital Inc. a percentage of revenues from the acquired technology, potentially transforming cancer care standards and enhancing LIXTE’s corporate growth.
More about Lixte Biotechnology Holdings
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies. The company is advancing cancer treatments with its lead compound, LB-100, a PP2A inhibitor, which is part of a new field of cancer biology known as activation lethality. LIXTE is conducting proof-of-concept clinical trials for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer.
Average Trading Volume: 125,697
Technical Sentiment Signal: Hold
Current Market Cap: $25.5M
See more data about LIXT stock on TipRanks’ Stock Analysis page.